{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:51:36Z","timestamp":1791474696345,"version":"4.3.4"},"reference-count":22,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"abstract":"\n Importance<\/jats:title>\n Nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, has been proposed as a potential disease-modifying therapy for Parkinson disease based on preclinical and early studies. Whether prolonged oral nicotinamide riboside improves clinical outcomes in Parkinson disease is unknown.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared with placebo.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway. Eligible participants were patients aged 35 years or older with Parkinson disease diagnosed within 2 years before enrollment, Hoehn and Yahr disease stage less than 3, abnormal dopamine transporter scintigraphy findings confirming dopaminergic nigrostriatal denervation, and stable dopaminergic treatment before enrollment. Of 537 screened individuals, 410 were randomized from May 6, 2020, to June 20, 2024, and 393 were included in the primary analysis. Final follow-up was completed on June 19, 2025.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Patients were randomized to receive oral nicotinamide riboside, 500 mg twice daily (n\u2009=\u2009206), or matching placebo (n\u2009=\u2009204) for 52 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was change from baseline to week 52 in the Movement Disorder Society Unified Parkinson Disease Rating Scale total score (MDS-UPDRS parts I-III; range, 0-236, with higher scores indicating more severe disease; clinically important differences for improvement and worsening, 6.7 and 5.2 points, respectively), analyzed using a mixed model for repeated measures. The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS; range, 0-360, with higher scores indicating greater nonmotor symptom burden).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 393 participants in the primary analysis, the mean age was 65.6 (SD, 9.4) years and 133 (34%) were female. At week 52, the total MDS-UPDRS score increased by 2.45 (95% CI, 0.80-4.10) points with nicotinamide riboside and decreased by 0.27 (95% CI, \u22121.95 to 1.40) points with placebo, yielding an adjusted mean difference of 2.72 points (95% CI, 0.47-4.98 points;\n P<\/jats:italic>\n \u2009=\u2009.02), favoring placebo. Of the 5 prespecified key secondary outcomes, 4 showed no significant difference, but nonmotor symptom burden worsened more with nicotinamide riboside (NMSS score adjusted mean difference, 4.22 [95% CI, 1.07-7.37] points;\n P<\/jats:italic>\n \u2009=\u2009.009). Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03568968<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.18828","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:00:44Z","timestamp":1791471644000},"source":"Crossref","is-referenced-by-count":0,"title":["Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease"],"prefix":"10.1001","author":[{"given":"Brage","family":"Brakedal","sequence":"first","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir Olve","family":"Skeie","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Derad","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl Bj\u00f8rnar","family":"Alstadhaug","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bod\u00f8 Hospital, Bod\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingunn","family":"Anundsk\u00e5s","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haakon","family":"Berven","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Biermann","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nuclear Medicine\/PET Centre, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Anne","family":"Bj\u00f8rnar\u00e5","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vestre Viken Hospital, Drammen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamila N.","family":"Torres Cleuren","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solveig E. J.","family":"Dalbro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eidelberg","sequence":"additional","affiliation":[{"name":"Center for Neurosciences, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York"},{"name":"Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjartan","family":"Foldnes","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nuclear Medicine\/PET Centre, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Fortes","sequence":"additional","affiliation":[{"name":"Department of Neurology, \u00d8stfold Hospital, Fredrikstad, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Haugarvoll","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Herlofson","sequence":"additional","affiliation":[{"name":"S\u00f8rlandsklinikken, Arendal, Norway"},{"name":"Department of Research, S\u00f8rlandet Hospital, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldbj\u00f8rg","family":"Hustad","sequence":"additional","affiliation":[{"name":"Department of Neurology, Molde Hospital, Molde, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelfien Ida","family":"HogenEsch","sequence":"additional","affiliation":[{"name":"Department of Neurology, Fonna Hospital Trust, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gard Aasmund Skulstad","family":"Johanson","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein Harald","family":"Johnsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Northern Norway, Troms\u00f8, Norway"},{"name":"Department of Clinical Medicine, UiT the Arctic University of Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Kunszt","sequence":"additional","affiliation":[{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kverneng","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaksei","family":"Labusau","sequence":"additional","affiliation":[{"name":"Department of Neurology, F\u00f8rde Hospital, F\u00f8rde, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg Haugesag","family":"Lie","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hallvard","family":"Lilleng","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital Northern Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Lundervold","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christofer","family":"Lundqvist","sequence":"additional","affiliation":[{"name":"Department of Neurology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"University of Oslo, Campus Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilong","family":"Ma","sequence":"additional","affiliation":[{"name":"Center for Neurosciences, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York"},{"name":"Department of Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"McCann","sequence":"additional","affiliation":[{"name":"Bevital AS, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tormund Haugland","family":"Nj\u00f8lstad","sequence":"additional","affiliation":[{"name":"Department of Radiology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Pihlstr\u00f8m","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Riemer","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Kaja","family":"Rognerud","sequence":"additional","affiliation":[{"name":"Department of Neurology, Vestre Viken Hospital, Drammen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Sheard","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel Meyer","family":"Simonsen","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bod\u00f8 Hospital, Bod\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Storm","sequence":"additional","affiliation":[{"name":"Department of Neurology, Molde Hospital, Molde, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Svensen","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilah","family":"Toker","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon-Anders","family":"Tunold","sequence":"additional","affiliation":[{"name":"Department of Neurology, Oslo University Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"D\u00f6lle","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen, G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Tzoulis","sequence":"additional","affiliation":[{"name":"Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway"},{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"joi260113r1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021.","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"issue":"12","key":"joi260113r2","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.tem.2025.03.013","article-title":"NAD augmentation as a disease-modifying strategy for neurodegeneration.","volume":"36","author":"D\u00f6lle","year":"2025","journal-title":"Trends Endocrinol Metab"},{"issue":"9","key":"joi260113r3","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1038\/s43587-025-00947-6","article-title":"Emerging strategies, applications and challenges of targeting NAD+ in the clinic.","volume":"5","author":"Zhang","year":"2025","journal-title":"Nat Aging"},{"issue":"6265","key":"joi260113r4","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aac4854","article-title":"NAD+ in aging, metabolism, and neurodegeneration.","volume":"350","author":"Verdin","year":"2015","journal-title":"Science"},{"issue":"10","key":"joi260113r5","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1016\/j.celrep.2018.05.009","article-title":"The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson\u2019s disease.","volume":"23","author":"Sch\u00f6ndorf","year":"2018","journal-title":"Cell Rep"},{"issue":"4","key":"joi260113r6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02263483","article-title":"The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.","volume":"1","author":"Birkmayer","year":"1989","journal-title":"J Neural Transm Park Dis Dement Sect"},{"issue":"1","key":"joi260113r7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0925-4439(97)00016-1","article-title":"NADH stimulates endogenous dopamine biosynthesis by enhancing the recycling of tetrahydrobiopterin in rat phaeochromocytoma cells.","volume":"1361","author":"Vrecko","year":"1997","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"joi260113r8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmet.2022.02.001","article-title":"The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson\u2019s disease.","volume":"34","author":"Brakedal","year":"2022","journal-title":"Cell Metab"},{"issue":"1","key":"joi260113r9","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1038\/s41467-023-43514-6","article-title":"NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson\u2019s disease.","volume":"14","author":"Berven","year":"2023","journal-title":"Nat Commun"},{"issue":"15","key":"joi260113r10","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"issue":"5","key":"joi260113r11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/mds.27303","article-title":"Are the MDS-UPDRS-based composite scores clinically applicable?","volume":"33","author":"Makkos","year":"2018","journal-title":"Mov Disord"},{"issue":"5","key":"joi260113r12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","article-title":"Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale.","volume":"32","author":"Horv\u00e1th","year":"2017","journal-title":"Mov Disord"},{"issue":"12","key":"joi260113r13","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","article-title":"Minimal clinically important difference on the motor examination part of MDS-UPDRS.","volume":"21","author":"Horv\u00e1th","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"joi260113r14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease.","volume":"26","author":"Martinez-Martin","year":"2011","journal-title":"Mov Disord"},{"issue":"1","key":"joi260113r15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","article-title":"Progression of MDS-UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s Progression Markers Initiative Cohort.","volume":"5","author":"Holden","year":"2018","journal-title":"Mov Disord Clin Pract"},{"issue":"5","key":"joi260113r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26479","article-title":"Bridging the gap between statistical significance and clinical relevance: a systematic review of minimum clinically important difference (MCID) thresholds of scales reported in movement disorders research.","volume":"10","author":"Mishra","year":"2024","journal-title":"Heliyon"},{"issue":"12","key":"joi260113r17","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2022.3718","article-title":"Evaluation of simvastatin as a disease-modifying treatment for patients with Parkinson disease: a randomized clinical trial.","volume":"79","author":"Stevens","year":"2022","journal-title":"JAMA Neurol"},{"issue":"10479","key":"joi260113r18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"joi260113r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.114764","article-title":"The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation.","volume":"29","author":"Berven","year":"2026","journal-title":"iScience"},{"issue":"3","key":"joi260113r20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/nbm.3455","article-title":"Repeatability of 31P MRSI in the human brain at 7T with and without the nuclear Overhauser effect.","volume":"29","author":"Lagemaat","year":"2016","journal-title":"NMR Biomed"},{"issue":"9","key":"joi260113r21","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.70362","article-title":"Metabolite-specific reproducibility of cerebral 31P-MRS at 3T: implications for clinical research.","volume":"39","author":"Svensen","year":"2026","journal-title":"NMR Biomed"},{"issue":"14","key":"joi260113r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34355","article-title":"Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson\u2019s disease.","volume":"10","author":"Turconi","year":"2024","journal-title":"Heliyon"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2855023\/jama_brakedal_2026_oi_260113_1790886794.20918.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:00:45Z","timestamp":1791471645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2855023"}},"subtitle":["The NOPARK Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1001\/jama.2026.18828","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}